Candego-8/Candego-16

Candesartan cilexetil

Alone or in combination w/ other antihypertensive agents for HTN. Heart failure (NYHA class II-IV) w/ left ventricular systolic dysfunction.

Dosage must be individualized. HTN Usual starting dose is 16 mg once daily, may be given bid w/ total daily doses from 8-32 mg. Heart failure Initially 4 mg once daily, increased at approx 2-wk intervals to achieve target dose of 32 mg once daily.

May be taken with or without food.

Hypersensitivity.

Close monitoring of renal function, electrolytes & BP if dual blockade of renin-angiotensin-aldosterone system is necessary. Patients on haemodialysis. May increase blood urea & serum creatinine in patients w/ bilateral renal artery stenosis or stenosis of the artery to a solitary kidney. Patients who have undergone renal transplant. Hypotension may occur in hypertensive patients w/ intravascular vol depletion such as receiving high dose diuretics. Anaesth & surgery. Haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy. Not recommended in patients w/ primary hyperaldosteronism. Periodic monitoring of serum K in patients w/ heart failure. Concomitant therapy w/ ACE inhibitor in heart failure; concomitant use w/ K-sparing diuretics, K supplements, salt substitutes containing K, or other medicinal products that may increase K levels (eg, heparin, co-trimoxazole). Treatment w/ other medicinal product affecting renin-angiotensin-aldosterone system in patients whose vascular tone & renal function depends on the system activity (eg, patients w/ severe CHF or underlying renal disease, including renal artery stenosis), may cause acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. Pregnancy & lactation. Childn w/ GFR <30 mL/min/1.73 m².

Asthenia, fever; paresthesia, vertigo; dyspepsia, gastroenteritis; tachycardia, palpitation; increased creatinine phosphokinase, hyperglycemia, hypertriglyceridemia, hyperuricemia; myalgia; epistaxis; anxiety, depression, somnolence; dyspnea; rash, increased sweating; hematuria.

Concomitant use w/ K-sparing diuretics, K supplements, salt substitutes containing K, or other medicinal products (eg, heparin) may increase K levels. Dual blockade of the RAAS w/ AIIRAs, ACE inhibitors, or aliskiren. Concomitant administration w/ lithium may increase serum lithium conc & toxicity (reversible). Increased antihypertensive effects w/ NSAIDs (eg, selective COX-2 inhibitors, ASA (>3 g/day) & non-selective NSAIDs). Increased risk of worsening of renal function, including possible acute renal failure, & increase in serum K w/ NSAIDs.

Angiotensin II Antagonists

C09CA06 - candesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx